Jack Georgakis, diagnosed with aggressive gastroesophageal junction cancer, recovered through a groundbreaking treatment ...

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by i ...

Japan reported an age-standardised incidence rate of 27.6 per 100,000 people in 2022, with 126,000 new cases diagnosed each ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Overall, 35% of patients' records had evidence of comprehensive genomic profiling (CGP). The rate increased modestly from 32% ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Topline data were announced from a phase 3 trial evaluating bemarituzumab plus chemotherapy in individuals with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with chemotherapy, according to interim data from a late-stage study.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in gastrointestinal cancer.